Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia.

Abstract

Waldenström's macroglobulinemia (WM) is an indolent lym phomaand is responsive to therapy regimens containing alkylating agents, purine analogs and rituximab if treatment becomes necessary. We initiated a multicenter phase II trial to determine the safety and efficacy of a regimen containing pentostatin, cyclophosphamide and rituximab (PER) in patients with WM. Between May 2005 and December 2010, 25 patients with WM were included in the study. Twenty-one patients received PER as first-line therapy. In these patients, 2-year progression-free survival was 83.6% and 2-year overall survival was 100%. Thirteen patients (52%) received R maintenance therapy. In these patients, the 2-year progression-free survival was 91.67% and 2-year overall survival was 100%. We have provided evidence that PER is a safe and effective regimen for WM. Although R maintenance therapy after PER seemed to induce a better long-term outcome, this study was not powered to address this issue.

• Authors: Isabelle Herth, Manfred Hensel, Michael Rieger, Kristin Horstmann, Wolfgang Hiddemann, Martin Dreyling, Silvia Koniczek, Mathias Witzens-Harig, Anthony D Ho
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 56 Issue 1 Pg. 97-102 (Jan 2015) ISSN: 1029-2403 [Electronic] United States
• PMID: 24724778 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• Pentostatin
• Rituximab
• Cyclophosphamide

Topics

• Adult
• Aged
• Antibodies, Monoclonal, Murine-Derived (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Cyclophosphamide (administration & dosage)
• Female
• Humans
• Male
• Middle Aged
• Pentostatin (administration & dosage)
• Rituximab
• Treatment Outcome
• Waldenstrom Macroglobulinemia (diagnosis, drug therapy, mortality)